|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0027 - 0.0033|
|52 Week Range||0.0027 - 0.0600|
|Beta (3Y Monthly)||-3.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HOUSTON, TX, April 22, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN), a leading developer of dietary supplements, is pleased to announce a one-year advertising.
HOUSTON, TX, April 15, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN), a leading developer of dietary supplements and biotechnology research and development company,.
HOUSTON, TEXAS, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma, Inc. (SOAN) is concerned that economic costs of diabetes in the USA were $327 BILLION in 2017, as reported by the American Diabetes Association. Of that total, $98 BILLION was spent on diabetic hospital admissions and $10.9 BILLION on diabetic neuropathy alone. Diabetes Relief’s patients report marked improvement in neuropathy as well as fewer hospitalizations, and testimonials are available at www.diabetesrelief.com.
HOUSTON, TX, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma, Inc. (SOAN) announces that Diabetes Relief LLC has licensed a new facility in San Antonio, Texas for its patented treatment, which is about to open. “Diabetes Relief is proud of this facility, which is an important cog in our expansion wheel as we move further west into Texas,” said Dr. Stanley T. Lewis, Chief Medical Officer.
Houston, TX, March 06, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company is excited about recent news of accomplishments of Diabetes Relief.
DALLAS , Dec. 28, 2018 /PRNewswire/ -- eQuine Holdings, a Class II Multi-Family Office, has disclosed an eight percent (8%) equity stake in AngioSoma (OTC-PINK:SOAN). On December 17, 2018 AngioSoma announced ...
Houston, TX, Dec. 14, 2018 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company has entered into a partially binding letter of intent to acquire 100%.
Peripheral Artery Disease Device Manufacturer Targeted for Joint Venture HOUSTON, Nov. 13, 2018 -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research.
Heart Health Focused Campaign Set to Kick Off December 1st, 2018 HOUSTON, TX, Nov. 12, 2018 -- via NEWMEDIAWIRE – AngioSoma (OTC: SOAN), a leading biotechnology research and.
New Industry Data and Product Roadmap Align for Optimistic Outlook HOUSTON, Nov. 08, 2018 -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research and.
The site, YouthfulBrilliance.com, features products within the Nutraceutical and Cosmeceutical industries currently with a future roadmap to expand product offerings with key partnerships and their growing Amazon storefront. AngioSoma is optimistic the new site launch paired with a new, innovative marketing plan will provide a solid foundation to continue research and development of new product lines designed to enhance lives. “The new YouthfulBrilliance.com sub-brand and website exemplifies AngioSoma’s innovative approach to the market and our unique target audience with a feature rich ecommerce site that sets the foundation for our future growth plans,” says Alex Blankenship, president of AngioSoma.
AngioSoma (SOAN) today announced they will organize the business into three new business units to meet specific and emerging market opportunities: Pharmaceuticals, Nutraceuticals, and Cosmeceuticals. “We have made great strides in the past six months to leverage our growing market strength and operational efficiencies,” said AngioSoma president and chief executive officer, Alex Blankenship. The first new division, Pharmaceuticals, focused exclusively on delivering innovative pharma-based solutions for the rapidly-growing, multi-billion-dollar medical market, will provide industry-leading research and development to provide treatment for many serious medical problems.
Original StemStrength™ was designed for men only but AngioSoma is excited to reveal the new StemStrength™ will be for both Women and Men, plus it will come in an AM and PM formulation. AngioSoma is excited to continue to innovate for its customers across the spectrum of health-related products.